Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  UCB SA    UNC   BE0003739530

UCB SA (UNC)

Delayed Quote. Delayed  - 09/30 08:02:04 am
67.948 EUR   -3.65%
09/26 UCB : and Amgen announce U.S. FDA acceptance of biologics licence ap..
09/26 UCB : Transparency notification
09/19 UCB : receives positive EU CHMP opinion for CIMZIA® (certolizumab pe..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Deutsche Boerse Ag
09/26/2016 09/27/2016 09/28/2016 09/29/2016 09/30/2016 Date
71.365(c) 70.321(c) 70.114(c) 70.521(c) 67.948(c) Last
0 0 0 0 0 Volume
-0.79% -1.46% -0.29% +0.58% -3.65% Change
More quotes
Financials (€)
Sales 2016 4 065 M
EBIT 2016 757 M
Net income 2016 471 M
Debt 2016 1 001 M
Yield 2016 1,83%
Sales 2017 4 321 M
EBIT 2017 898 M
Net income 2017 548 M
Debt 2017 653 M
Yield 2017 1,92%
P/E ratio 2016 26,65
P/E ratio 2017 21,67
EV / Sales2016 3,54x
EV / Sales2017 3,25x
Capitalization 13 388 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products for central nervous system and immunology disorders under the Cimzia, Xyzal, Zyrtec, Tussionex, Lortab, Vimpat, Keppra and Neupro.The company was founded by... 
Sector
Pharmaceuticals
Calendar
10/25Earnings Release
More about the company
Surperformance© ratings of UCB SA
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB SA
09/29 UCB : Opens Solution Accelerator at Georgia Tech Technology Square
09/26 UCB : and Amgen announce U.S. FDA acceptance of biologics licence application fo..
09/26 UCB : Transparency notification
09/19 UCB : receives positive EU CHMP opinion for CIMZIA® (certolizumab pegol) AutoCli..
09/18 UCB : Results from phase 3 Frame study of romosozumab showed significant reducti..
09/16 UCB : Transparency notification
09/08 UCB : Transparency notifications
08/29 DAIICHI SANKYO : Antiepileptic lacosamide filed for partial amendment of approva..
08/19 UCB : Transparency notification
08/18 UCB : Transparency notification
More news
Sector news : Pharmaceuticals - NEC
09/30DJGLAXOSMITHKLINE : to Pay $20 Million to Settle SEC Bribery Probe
09/30 GlaxoSmithKline to pay $20 million to settle U.S. foreign bribery case
09/30DJGLAXOSMITHKLINE : to Pay $20 Million to Settle SEC Bribery Probe
09/30DJSHIRE : Files 8K - Other Events
09/30DJNovo Nordisk Announces Job Cuts
More sector news : Pharmaceuticals - NEC
Advertisement
Chart UCB SA
Duration : Period :
UCB SA Technical Analysis Chart | UNC | BE0003739530 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 17
Average target price 79,0 €
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Gerhard N. Mayr Chairman
Mark D. McDade Chief Operating Officer & Executive Vice President
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Loew-Friedrich Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
UCB SA-20.19%15 048
JOHNSON & JOHNSON15.00%323 189
ROCHE HOLDING LTD.-12.52%214 851
NOVARTIS AG-11.00%207 776
PFIZER INC.4.93%205 444
MERCK & CO., INC.18.16%172 577
More Results